Prostate Cancer Outcomes of Docetaxel Alone or With Strontium-89 or...
The TRAPEZE study compares the clinical effectiveness and cost-effectiveness of docetaxel alone or with strontium-89, zoledronic acid, or both in patients with bony metastatic castrate-refractory...
View ArticleNonrecommended Screening for Prostate Cancer and Breast Cancer
This survey study assesses the prevalence of nonrecommended screening for prostate cancer and breast cancer in the United States.
View ArticleDNA Damage and Repair Pathway Profiles and Prostatectomy
This cohort study of 1090 men tests 9 DNA damage and repair pathways using 17 gene sets from prostatectomy samples to identify better biomarkers for patients at the highest risk to guide therapy...
View ArticleTargeted Cancer Screening After Solid-Organ Transplantation
In this issue of JAMA Oncology, Acuna et al examine the association between solid-organ transplantation and cancer mortality in a population-based setting. By relying on robust methodology and linked...
View ArticleDNA Damage and Repair Pathways as Biomarkers in Prostate Cancer
A major challenge for clinicians in the management of prostate cancer is distinguishing patients with indolent disease from those with aggressive lethal variants of the disease at diagnosis. The...
View ArticleFailure-Free Survival and Nonmetastatic Prostate Cancer Radiotherapy
This study of patients allocated to the control arm of the STAMPEDE Trial explored the survival and the effect on survival of radiotherapy by nodal involvement in high-risk, hormone-naive men with...
View ArticleRadiation Therapy and Risk of Death in Node-Positive Prostate Cancer
Both single-institutional retrospective series and a multi-institutional observational study find a significant association between a reduced risk of death and treatment of node-positive prostate...
View ArticleProstate-Specific Antigen Screening and Selective Treatment
This modeling study analyzes 18 different strategies for prostate-specific antigen (PSA) screening with 2 treatment strategies for increased PSA levels in a cohort of US men 40 years or older.
View ArticlePSA Screening—Does It Do More Harm Than Good?
Early detection for prostate cancer using the prostate-specific antigen (PSA) test remains controversial. Until relatively recently, this controversy revolved around whether use of the test actually...
View ArticleRecent Trends in PSA Testing and Prostate Cancer Incidence
This summary of an article published in JAMA examines prostate cancer incidence trends and prostate-specific antigen screening rates following the 2008 and 2012 USPSTF recommendations.
View ArticleUrine Exosome Signature to Predict High-Grade Prostate Cancer
This cohort validation study evaluates the performance of a novel urine exosome assay plus standard of care for discriminating Gleason score (GS)7 from GS6 and benign prostate disease on initial biopsy.
View ArticleImproving Prostate Cancer Screening and Diagnosis
The initial goal of prostate cancer screening with prostate-specific antigen (PSA) was to identify men with early-stage disease according to the general oncologic principle of secondary prevention that...
View ArticleDescribing Differences in Survival Curves
We congratulate Péron et al on their contribution to the medical canon of a new measure of survival time treatment effect in a clinical trial. This measure, which equals the chance of surviving longer...
View ArticleEnzalutamide Resistance in Castration-Resistant Prostate Cancer
This genomic profiling study investigates the genomic mechanisms underpinning resistance to the androgen receptor antagonist enzalutamide in metastatic castration-resistant prostate cancer.
View ArticleReplacing Urban Myths About Cancer With Community Wisdom Putting a Finger on...
In the examination room was Rodney, an “otherwise healthy” 47-year-old black man with newly diagnosed, high-grade prostate cancer (PC). Exuding an enthusiasm rarely seen in my clinic, he said, “Finger...
View ArticleAR-V7 Expression in Circulating Tumor Cells and Castration-Resistant Prostate...
This cohort study compares outcomes among men with metastatic castration-resistant prostate cancer with vs without preandrogen receptor signaling (ARS) inhibitor AR-V7 protein in circulating tumor...
View ArticleAR-V7 Protein in Circulating Tumor Cells
In this issue of JAMA Oncology, Scher et al present additional evidence that the presence of the constitutively active androgen receptor variant 7 (AR-V7) is a marker for resistance to standard...
View ArticleCurrent Status of Prostate Cancer Diagnosis and Management
This study used a hospital-based national cancer registry to assess prostate cancer diagnosis and management trends in the United States.
View ArticleUse of Androgen Deprivation Therapy for Prostate Cancer
This study uses data from the US National Cancer Data Base to examine the adoption of androgen deprivation therapy vs dose-escalated radiotherapy for prostate cancer across the United States.
View ArticleUrine Exosome Signature to Predict High-Grade Prostate Cancer
This cohort validation study evaluates the performance of a novel urine exosome assay plus standard of care for discriminating Gleason score (GS)7 from GS6 and benign prostate disease on initial biopsy.
View Article
